This is a phase 1b/2 study to determine the safety and effectiveness of the combination of
pembrolizumab and idelalisib in NSCLC patients whose disease has stopped responding to immune
therapy. This study is being done to see if adding another immune modulator (idelalisib) to
standard pembrolizumab will increase response rates, compared to the response seen with
pembrolizumab alone.